

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elizabeth M. Denholm, Yong-Qing Lin, and Paul J. Silver

Serial No.: 10/623,383

Filed: July 18, 2003

For: ATTENUATION OF TUMOR GROWTH, METASTASIS AND ANGIOGENESIS

Commissioner for Patents Washington, D.C. 20231

## POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST AND REVOCATION OF PRIOR POWERS

Sir:

As owner of the entire interest in the above-identified patent application, as evidenced by the attached Statement Under 37 C.F.R. § 3.73(b), all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabst Registration No. 31,284
Rivka D. Monheit Registration No. 48,731
Todd S. Hofmeister Registration No. 53,029

Please send all correspondence relating to the above-identified patent application to:

Customer No. 23579
Patrea L. Pabst
HOLLAND & KNIGHT LLP
Suite 2000, One Atlantic Center
1201 West Peachtree Street, N.E.
Atlanta, Georgia 30309-3400

(404) 817-8473 (Telephone) (404) 817-8588 (Fax)

Continuation of U.S.S.N. 09/715,965

Filed: July 18, 2003

Power of Attorney by Assignee of Entire Interest and Revocation of Prior Powers

The undersigned signatory (whose title is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of the undersigned's knowledge and belief, title is in the assignee.

**BIOMARIN ENZYMES INC.** 

By:\_

Printed Name:

(A) C ... 11 (

Data: Q/4/

ATL1 #586113 v1

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Elizabeth M. Denholm, Y	ong-Qing Lin, and Paul J. Silver	
Application No./Patent No.: 10/623, 383 Filed/Issue Date: July 18, 2003		
Entitled: Attenuation of Tumor Growth, Metastasis and Angiogenesis		
BioMarin Enzyme Inc.	corporation of the State of Delaware	
	ssignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:		
1. 🗷 the assignee of the entire right, title, and interest; or		
2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is%		
in the patent application/patent identified above by virtue of either:		
A. [ ] An assignment from the inventor(s) of the patent was recorded in the United States Patent and Townich a copy thereof is attached.	t application/patent identified above. The assignment rademark Office at Reel, Frame, or for	
OR		
B. [x] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:    Elizabeth M. Denholm, Yong-Qing Lin,		
3. From:	То:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
[ ] Additional documents in the chain of title are listed on a supplemental sheet.		
	ent document or a true copy of the original document) lance with 37 CFR Part 3, if the assignment is to be	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
9/4/03	Christopher M. Starr	
Date	Typed or printed name	
	Signature	
	Senior Vice President, Scientific  Title Operations	
	ille Operations	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/623, 383 10/623,383 **TRANSMITTAL** Filing Date July 18, 2003 **FORM** First Named Inventor Elizabeth M. Denholm Art Unit 1651 (to be used for all correspondence after initial filing)

Examiner Name

Total Number of Pages in This Submission	Attorney Docket Number	IT 106 CON	
Total Number of Pages in This Submission			
ENCLOSURES (Check all that apply)			
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund	After Allowance communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):  Statement Under 37 CFR 3.73(b); Return Postcard	
Information Disclosure Statement	CD, Number of CD(s)		
Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Patrea L. Pabst/ Esq., Reg. No. 31,284 Holland & Knight LLP Individual name Suite 2000, One Atlantic Center; 1201 West Peachtree Street, N.E.; Atlanta, GA 30309-3400			
Signature			
Date November 4,2003			
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name  Jean Hicks			
Signature	a Huls	Date November 4, 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.